Marengo Reports Phase 2 Breast Cancer Data at AACR
CAMBRIDGE, Mass., April 17, 2026 Marengo Therapeutics, Inc. announced late-breaking Phase 2 clinical results for its investigational immunotherapy invikafusp...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
CAMBRIDGE, Mass., April 17, 2026 Marengo Therapeutics, Inc. announced late-breaking Phase 2 clinical results for its investigational immunotherapy invikafusp...
San Diego, USA & Suzhou, China, April 2, 2026 Strong Clinical Efficacy in MSS Colorectal Cancer In a major...
South San Francisco, California, USA, April 6, 2026 First-in-Class Epigenetic Therapy Enters Clinical Development In a major step forward...
SHANGHAI, China, April 1, 2026 Shanghai Henlius Biotech, Inc. announced that the China National Medical Products Administration (NMPA) has...
BASEL, Switzerland, March 20, 2026 Novartis announced a major strategic acquisition to strengthen its oncology portfolio, agreeing to acquire...
New York, USA | March 17, 2026 Pfizer has announced positive topline results from its Phase 2 FOURLIGHT-1 clinical...
PALO ALTO, CA — December 5, 2025 — Guardant Health announced it will present 14 abstracts at the 2025...
Philadelphia, PA and Vancouver, BC — December 2, 2025 — BriaCell Therapeutics Corp. announced plans to present three major...
South San Francisco, Calif. – October 30, 2025 — BridgeBio Oncology Therapeutics, Inc. (BBOT) announced two poster presentations at...
BASEL, Switzerland, Sept. 26, 2025 — Novartis announced it will present 34 abstracts from its oncology pipeline at the...
